Literature DB >> 33442540

Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition).

Jian Zhou1, Huichuan Sun1, Zheng Wang1, Wenming Cong2, Jianhua Wang3, Mengsu Zeng4, Weiping Zhou5, Ping Bie6, Lianxin Liu7, Tianfu Wen8, Guohong Han9, Maoqiang Wang10, Ruibao Liu11, Ligong Lu12, Zhengang Ren1, Minshan Chen13, Zhaochong Zeng14, Ping Liang15, Changhong Liang16, Min Chen17, Fuhua Yan18, Wenping Wang19, Yuan Ji20, Jingping Yun21, Dingfang Cai22, Yongjun Chen23, Wenwu Cheng24, Shuqun Cheng5, Chaoliu Dai25, Wenzhi Guo26, Baojin Hua27, Xiaowu Huang1, Weidong Jia28, Yaming Li29, Yexiong Li30, Jun Liang31, Tianshu Liu32, Guoyue Lv33, Yilei Mao34, Tao Peng35, Weixin Ren36, Hongcheng Shi37, Guoming Shi1, Kaishan Tao38, Wentao Wang8, Xiaoying Wang1, Zhiming Wang39, Bangde Xiang40, Baocai Xing41, Jianming Xu42, Jiamei Yang5, Jianyong Yang43, Yefa Yang44, Yunke Yang22, Shenglong Ye1, Zhengyu Yin45, Bixiang Zhang46, Boheng Zhang1, Leida Zhang47, Shuijun Zhang48, Ti Zhang49, Yongfu Zhao48, Honggang Zheng50, Jiye Zhu51, Kangshun Zhu52, Rong Liu3, Yinghong Shi1, Yongsheng Xiao1, Zhi Dai1, Gaojun Teng53, Jianqiang Cai54, Weilin Wang55, Xiujun Cai56, Qiang Li49, Feng Shen5, Shukui Qin57, Jiahong Dong58, Jia Fan1.   

Abstract

BACKGROUND: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people.
SUMMARY: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition (2019 Edition) was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. KEY MESSAGES: Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People's Republic of China in December 2019.
Copyright © 2020 by S. Karger AG, Basel.

Entities:  

Keywords:  Cancer; Carcinoma; China; Diagnosis; Liver; Treatment

Year:  2020        PMID: 33442540      PMCID: PMC7768108          DOI: 10.1159/000509424

Source DB:  PubMed          Journal:  Liver Cancer        ISSN: 1664-5553            Impact factor:   11.740


  200 in total

1.  Determination of clonal origin of recurrent hepatocellular carcinoma for personalized therapy and outcomes evaluation: a new strategy for hepatic surgery.

Authors:  Bin Wang; Chun-Yan Xia; Wan-Yee Lau; Xin-Yuan Lu; Hui Dong; Wen-Long Yu; Guang-Zhi Jin; Wen-Ming Cong; Meng-Chao Wu
Journal:  J Am Coll Surg       Date:  2013-12       Impact factor: 6.113

2.  Outcomes After Stereotactic Body Radiotherapy or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng
Journal:  J Clin Oncol       Date:  2015-11-30       Impact factor: 44.544

Review 3.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

4.  Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.

Authors:  Tomoaki Ichikawa; Kazuhiro Saito; Naoki Yoshioka; Akihiro Tanimoto; Takehiko Gokan; Yasuo Takehara; Takeshi Kamura; Toshifumi Gabata; Takamichi Murakami; Katsuyoshi Ito; Shinji Hirohashi; Akihiro Nishie; Yoko Saito; Hiroaki Onaya; Ryohei Kuwatsuru; Atsuko Morimoto; Koji Ueda; Masayo Kurauchi; Josy Breuer
Journal:  Invest Radiol       Date:  2010-03       Impact factor: 6.016

5.  Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with Barcelona Clinic Liver Cancer stages 0 and A hepatocellular carcinomas: a multicenter retrospective cohort study.

Authors:  Seung Hyup Hyun; Jae Seon Eo; Jeong Won Lee; Joon Young Choi; Kyung-Han Lee; Sae Jung Na; Il Ki Hong; Jin Kyoung Oh; Yong An Chung; Bong-Il Song; Tae-Sung Kim; Kyung Sik Kim; Dae Hyuk Moon; Mijin Yun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-03-02       Impact factor: 9.236

6.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

7.  No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.

Authors:  Kayvan Mohkam; Paul-Noël Dumont; Anne-Frédérique Manichon; Jean-Christophe Jouvet; Loïc Boussel; Philippe Merle; Christian Ducerf; Mickaël Lesurtel; Agnès Rode; Jean-Yves Mabrut
Journal:  J Hepatol       Date:  2018-02-02       Impact factor: 25.083

8.  Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Andrew X Zhu; Yoon-Koo Kang; Chia-Jui Yen; Richard S Finn; Peter R Galle; Josep M Llovet; Eric Assenat; Giovanni Brandi; Marc Pracht; Ho Yeong Lim; Kun-Ming Rau; Kenta Motomura; Izumi Ohno; Philippe Merle; Bruno Daniele; Dong Bok Shin; Guido Gerken; Christophe Borg; Jean-Baptiste Hiriart; Takuji Okusaka; Manabu Morimoto; Yanzhi Hsu; Paolo B Abada; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2019-01-18       Impact factor: 41.316

9.  Randomized controlled trial of screening for hepatocellular carcinoma.

Authors:  Bo-Heng Zhang; Bing-Hui Yang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

10.  Comparison of hepatic resection and radiofrequency ablation for small hepatocellular carcinoma: a meta-analysis of 16,103 patients.

Authors:  Qinghua Xu; Seijin Kobayashi; Xun Ye; Xia Meng
Journal:  Sci Rep       Date:  2014-11-28       Impact factor: 4.379

View more
  101 in total

1.  Comparison of a preoperative MR-based recurrence risk score versus the postoperative score and four clinical staging systems in hepatocellular carcinoma: a retrospective cohort study.

Authors:  Hong Wei; Hanyu Jiang; Yun Qin; Yuanan Wu; Jeong Min Lee; Fang Yuan; Tianying Zheng; Ting Duan; Zhen Zhang; Yali Qu; Jie Chen; Yuntian Chen; Zheng Ye; Shan Yao; Lin Zhang; Ting Yang; Bin Song
Journal:  Eur Radiol       Date:  2022-05-13       Impact factor: 5.315

Review 2.  Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition).

Authors:  Hui-Chuan Sun; Jian Zhou; Zheng Wang; Xiufeng Liu; Qing Xie; Weidong Jia; Ming Zhao; Xinyu Bi; Gong Li; Xueli Bai; Yuan Ji; Li Xu; Xiao-Dong Zhu; Dousheng Bai; Yajin Chen; Yongjun Chen; Chaoliu Dai; Rongping Guo; Wenzhi Guo; Chunyi Hao; Tao Huang; Zhiyong Huang; Deyu Li; Gang Li; Tao Li; Xiangcheng Li; Guangming Li; Xiao Liang; Jingfeng Liu; Fubao Liu; Shichun Lu; Zheng Lu; Weifu Lv; Yilei Mao; Guoliang Shao; Yinghong Shi; Tianqiang Song; Guang Tan; Yunqiang Tang; Kaishan Tao; Chidan Wan; Guangyi Wang; Lu Wang; Shunxiang Wang; Tianfu Wen; Baocai Xing; Bangde Xiang; Sheng Yan; Dinghua Yang; Guowen Yin; Tao Yin; Zhenyu Yin; Zhengping Yu; Bixiang Zhang; Jialin Zhang; Shuijun Zhang; Ti Zhang; Yamin Zhang; Yubao Zhang; Aibin Zhang; Haitao Zhao; Ledu Zhou; Wu Zhang; Zhenyu Zhu; Shukui Qin; Feng Shen; Xiujun Cai; Gaojun Teng; Jianqiang Cai; Minshan Chen; Qiang Li; Lianxin Liu; Weilin Wang; Tingbo Liang; Jiahong Dong; Xiaoping Chen; Xuehao Wang; Shusen Zheng; Jia Fan
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

3.  Is FOLFOX-HAIC superior to transarterial chemoembolization in treating large hepatocellular carcinoma?

Authors:  Yun-Shi Cai; Hong Wu
Journal:  Hepatobiliary Surg Nutr       Date:  2022-02       Impact factor: 7.293

4.  Serum N-glycan profiling as a diagnostic biomarker for the identification of hepatitis B virus-associated hepatocellular carcinoma.

Authors:  Li Guo; Lijun Wan; Youwen Hu; Hongyan Huang; Bo He; Zhili Wen
Journal:  J Gastrointest Oncol       Date:  2022-02

5.  Machine Learning to Improve Prognosis Prediction of Early Hepatocellular Carcinoma After Surgical Resection.

Authors:  Gu-Wei Ji; Ye Fan; Dong-Wei Sun; Ming-Yu Wu; Ke Wang; Xiang-Cheng Li; Xue-Hao Wang
Journal:  J Hepatocell Carcinoma       Date:  2021-08-10

6.  A Radiomics Nomogram for Preoperative Prediction of Early Recurrence of Small Hepatocellular Carcinoma After Surgical Resection or Radiofrequency Ablation.

Authors:  Liting Wen; Shuping Weng; Chuan Yan; Rongping Ye; Yuemin Zhu; Lili Zhou; Lanmei Gao; Yueming Li
Journal:  Front Oncol       Date:  2021-04-29       Impact factor: 6.244

7.  Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma.

Authors:  Zhi-Cheng Jin; Li Chen; Bin-Yan Zhong; Hai-Dong Zhu; Chu-Hui Zeng; Rui Li; Jin-He Guo; Shi-Cheng He; Gang Deng; Xiao-Li Zhu; Cai-Fang Ni; Gao-Jun Teng
Journal:  Front Oncol       Date:  2021-05-06       Impact factor: 6.244

8.  Risk factors of infection after transarterial chemoembolization for hepatocellular carcinoma: A protocol for systematic review and meta-analysis.

Authors:  Zhipeng Shi; Wen Yang; Hao Tang; Xiuhong Li
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

9.  MIF promoter polymorphism increases peripheral blood expression levels, contributing to increased susceptibility and poor prognosis in hepatocellular carcinoma.

Authors:  Lifeng Qin; Jinmei Qin; Xiaoping Lv; Caiqiao Yin; Qian'e Zhang; Jiqiao Zhang
Journal:  Oncol Lett       Date:  2021-05-24       Impact factor: 2.967

Review 10.  Evolving Treatment of Advanced Hepatocellular Carcinoma in the Asia-Pacific Region: A Review and Multidisciplinary Expert Opinion.

Authors:  Sadahisa Ogasawara; Su-Pin Choo; Jiang-Tao Li; Changhoon Yoo; Bruce Wang; Dee Lee; Pierce K H Chow
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.